Veramarx offers the only accurate diagnostic test for early-stage Lyme disease, which is one of the fastest growing infectious disease in the US and Western Europe. Lyme disease can only be treated effectively when diagnosed at the early stage of infection, when 75% of patients visit the doctor. Current tests are highly inaccurate, missing over 60%of the cases in the early stage. The proprietary Veramarx test is 92% sensitive at the critical early stage of Lyme disease infection, when the disease is still treatable. Veramarx also has 99% negative predictive value, to rule out Lyme disease.

Veramarx, Inc.

Org chart

Similar companies